SK281035B6 - Spôsob prípravy esterov baccatínu iii alebo 10-desacetylbaccatínu iii, ester baccatínu iii alebo 10-desacetylbaccatínu iii a medziprodukt na uvedený spôsob - Google Patents

Spôsob prípravy esterov baccatínu iii alebo 10-desacetylbaccatínu iii, ester baccatínu iii alebo 10-desacetylbaccatínu iii a medziprodukt na uvedený spôsob Download PDF

Info

Publication number
SK281035B6
SK281035B6 SK438-95A SK43895A SK281035B6 SK 281035 B6 SK281035 B6 SK 281035B6 SK 43895 A SK43895 A SK 43895A SK 281035 B6 SK281035 B6 SK 281035B6
Authority
SK
Slovakia
Prior art keywords
group
iii
carbon atoms
formula
atom
Prior art date
Application number
SK438-95A
Other languages
English (en)
Slovak (sk)
Other versions
SK43895A3 (en
Inventor
Jean-Noel Denis
Andrew Greene
Jean-Manuel Mas
Original Assignee
Rhone-Poulenc Rorer S. A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone-Poulenc Rorer S. A. filed Critical Rhone-Poulenc Rorer S. A.
Publication of SK43895A3 publication Critical patent/SK43895A3/sk
Publication of SK281035B6 publication Critical patent/SK281035B6/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D305/00Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epoxy Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
SK438-95A 1992-10-05 1993-10-04 Spôsob prípravy esterov baccatínu iii alebo 10-desacetylbaccatínu iii, ester baccatínu iii alebo 10-desacetylbaccatínu iii a medziprodukt na uvedený spôsob SK281035B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9211739A FR2696464B1 (fr) 1992-10-05 1992-10-05 Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III.
PCT/FR1993/000965 WO1994007876A1 (fr) 1992-10-05 1993-10-04 Nouveau procede d'esterification de la baccatine iii et de la desacetyl-10 baccatine iii

Publications (2)

Publication Number Publication Date
SK43895A3 SK43895A3 (en) 1995-08-09
SK281035B6 true SK281035B6 (sk) 2000-11-07

Family

ID=9434116

Family Applications (1)

Application Number Title Priority Date Filing Date
SK438-95A SK281035B6 (sk) 1992-10-05 1993-10-04 Spôsob prípravy esterov baccatínu iii alebo 10-desacetylbaccatínu iii, ester baccatínu iii alebo 10-desacetylbaccatínu iii a medziprodukt na uvedený spôsob

Country Status (24)

Country Link
US (2) US5717103A (ru)
EP (1) EP0663905B1 (ru)
JP (1) JP3064419B2 (ru)
KR (1) KR100290663B1 (ru)
AT (1) ATE147734T1 (ru)
AU (1) AU689446B2 (ru)
CA (1) CA2146372C (ru)
CZ (1) CZ284818B6 (ru)
DE (1) DE69307526T2 (ru)
DK (1) DK0663905T3 (ru)
ES (1) ES2096328T3 (ru)
FI (1) FI115909B (ru)
FR (1) FR2696464B1 (ru)
GR (1) GR3022286T3 (ru)
HU (1) HU225973B1 (ru)
MX (1) MX9305764A (ru)
NO (1) NO313141B1 (ru)
NZ (1) NZ256443A (ru)
PL (1) PL178090B1 (ru)
RU (1) RU2123493C1 (ru)
SK (1) SK281035B6 (ru)
TW (1) TW372234B (ru)
WO (1) WO1994007876A1 (ru)
ZA (1) ZA937316B (ru)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794523B2 (en) 1991-09-23 2004-09-21 Florida State University Taxanes having t-butoxycarbonyl substituted side-chains and pharmaceutical compositions containing them
FR2697522B1 (fr) * 1992-10-30 1994-11-25 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2698361B1 (fr) * 1992-11-20 1995-01-13 Rhone Poulenc Rorer Sa Procédé de préparation d'un acide oxazolidine-1,3 carboxylique-5.
IL107950A (en) 1992-12-15 2001-04-30 Upjohn Co b 7, b 8 - Matano - Taxols, their preparation and pharmaceutical preparations against malignant tumors containing them
ES2145829T3 (es) * 1993-06-11 2000-07-16 Upjohn Co Uso antineoplasico de delta 6,7-taxoles y composiciones farmaceuticas que los contienen.
DE69435342D1 (de) 1993-07-19 2011-05-05 Angiotech Pharm Inc Anti-Angiogene Mittel und Verfahren zu deren Verwendung
JPH09505050A (ja) * 1993-11-12 1997-05-20 ジ・アップジョン・カンパニー ピリミジン−チオアルキルおよびアルキルエーテル化合物
IL127599A (en) * 1994-01-28 2004-06-01 Upjohn Co Process for preparing isotaxol analogs
CA2178541C (en) 1995-06-07 2009-11-24 Neal E. Fearnot Implantable medical device
CZ293508B6 (cs) * 1996-05-08 2004-05-12 Pharmaciaá@Áupjohnácompany Fenylisoserinestery silylového baccatinu III
US6150537A (en) * 1997-12-12 2000-11-21 Emory University Methods for the esterification of alcohols and compounds useful therefor as potential anticancer agents
WO2002085337A1 (en) 2001-04-20 2002-10-31 The University Of British Columbia Micellar drug delivery systems for hydrophobic drugs
JP4502338B2 (ja) * 1999-09-17 2010-07-14 株式会社横浜国際バイオ研究所 タキソイド化合物の製造法
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
CA2307393A1 (en) 2000-05-01 2001-11-01 The University Of British Columbia Ginsenoside chemotherapy
EP1318794A2 (en) 2000-09-22 2003-06-18 Bristol-Myers Squibb Company Method for reducing toxicity of combined chemotherapies
CA2440935A1 (en) * 2001-03-13 2002-09-19 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
US20030157170A1 (en) * 2001-03-13 2003-08-21 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
JP2006516548A (ja) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
US20070172446A1 (en) 2003-05-16 2007-07-26 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
US7846940B2 (en) 2004-03-31 2010-12-07 Cordis Corporation Solution formulations of sirolimus and its analogs for CAD treatment
US7989490B2 (en) 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
US8003122B2 (en) 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
WO2006089209A2 (en) 2005-02-17 2006-08-24 The Board Of Trustees Of The Leland Stanford Junior University Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby
RU2448697C2 (ru) 2006-03-22 2012-04-27 Медигене Аг Лечение рака молочной железы, негативного по трем рецепторам
WO2008005284A2 (en) 2006-06-30 2008-01-10 Cook Incorporated Methods of manufacturing and modifying taxane coatings for implantable medical devices
US8409601B2 (en) 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
US8420110B2 (en) 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
US8273404B2 (en) 2008-05-19 2012-09-25 Cordis Corporation Extraction of solvents from drug containing polymer reservoirs
WO2009143454A2 (en) 2008-05-22 2009-11-26 Kereos, Inc. Combination antitumor therapy
PL2300489T3 (pl) 2008-06-06 2016-11-30 Sposoby wytwarzania 17-alkinylo-7-hydroksysteroidów i związków pokrewnych
EP2310507A4 (en) 2008-07-08 2013-03-20 David Gladstone Inst METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS
US8642063B2 (en) 2008-08-22 2014-02-04 Cook Medical Technologies Llc Implantable medical device coatings with biodegradable elastomer and releasable taxane agent
PL388144A1 (pl) 2009-05-29 2010-12-06 Przedsiębiorstwo Produkcyjno-Wdrożeniowe Ifotam Spółka Z Ograniczoną Odpowiedzialnością Solwaty (2R,3S)-3-tert-butoksykarbonylamino-2-hydroksy-3-fenylopropionianu 4-acetoksy-2α-benzoiloksy -5β,20-epoksy-1,7β,10β-trihydroksy-9-okso-taks-11-en-13α-ylu, sposób ich otrzymywania i zastosowanie
US20120302954A1 (en) 2011-05-25 2012-11-29 Zhao Jonathon Z Expandable devices coated with a paclitaxel composition
US20120303115A1 (en) 2011-05-25 2012-11-29 Dadino Ronald C Expandable devices coated with a rapamycin composition
US9956385B2 (en) 2012-06-28 2018-05-01 The Spectranetics Corporation Post-processing of a medical device to control morphology and mechanical properties
EP3539563A1 (en) 2012-07-19 2019-09-18 Redwood Bioscience, Inc. Antibody specific for cd22 and methods of use thereof
AU2013341711A1 (en) 2012-11-12 2015-05-21 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
ES2758227T3 (es) 2013-02-15 2020-05-04 Univ California Receptor de antígeno quimérico y métodos de uso del mismo
JP6410790B2 (ja) 2013-03-14 2018-10-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ミトコンドリアアルデヒドデヒドロゲナーゼ−2調節因子およびその使用方法
CA2927806C (en) 2013-11-27 2023-01-10 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
US9879036B2 (en) 2014-02-19 2018-01-30 Aviv Therapeutics, Inc. Mitochondrial aldehyde dehydrogenase-2 binding compounds and methods of use thereof
JP6083815B2 (ja) * 2014-03-07 2017-02-22 立川ブラインド工業株式会社 タッセル
CN108135917B (zh) 2015-09-25 2021-07-09 Zy医疗 基于包含多糖-维生素缀合物的颗粒的药物制剂
EP3373977A4 (en) 2015-11-12 2019-07-17 The Board of Trustees of the Leland Stanford Junior University CELLULAR PENETRATION-RICH GUANIDINIC OLIGOPHOSPHOTRIESTERS FOR THE DELIVERY OF MEDICATION AND PROBE
TWI760319B (zh) 2015-12-30 2022-04-11 杏國新藥股份有限公司 乳癌治療
WO2017189432A1 (en) 2016-04-26 2017-11-02 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
MX2018014916A (es) 2016-06-01 2019-07-18 Servier Ip Uk Ltd Formulaciones de oxido de polialquileno-asparaginasa y metodos de preparacion y uso del mismo.
WO2018127082A1 (en) 2017-01-05 2018-07-12 Syncore Biotechnology Co., Ltd. Treatment of pancreatic cancer
BR112019014615A2 (pt) 2017-01-18 2020-06-02 F1 Oncology, Inc. Receptores de antígeno quimérico contra axl ou ror2 e métodos de uso dos mesmos
EP3388082A1 (en) 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
EA202091832A1 (ru) 2018-01-31 2021-01-11 ГАЛЕРА ЛЭБЗ, ЭлЭлСи Комбинированная терапия злокачественных новообразований макроциклическим кольцевым комплексом пентаазы и противоопухолевым агентом на основе платины
US11660266B2 (en) 2018-04-11 2023-05-30 Ohio State Innovation Foundation Methods and compositions for sustained release microparticles for ocular drug delivery
MX2021000644A (es) 2018-07-18 2021-08-19 Manzanita Pharmaceuticals Inc Conjugados para suministrar un agente contra el cancer a las celulas nerviosas, metodos de uso y metodos para la elaboracion de los mismos.
WO2020148612A1 (en) 2019-01-14 2020-07-23 Ignite Immunotherapy, Inc. Recombinant vaccinia virus and methods of use thereof
US11685904B2 (en) 2019-02-14 2023-06-27 Ignite Immunotherapy, Inc. Recombinant vaccinia virus and methods of use thereof
EP3946626A1 (en) 2019-04-02 2022-02-09 Kenjockety Biotechnology, Inc. Efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
WO2021116943A1 (en) 2019-12-12 2021-06-17 Ignite Immunotherapy, Inc. Variant oncolytic vaccinia virus and methods of use thereof
MX2022009355A (es) 2020-01-29 2022-09-02 Kenjockety Biotechnology Inc Anticuerpo anti-mdr1 y uso del mismo.
US20230212305A1 (en) 2020-06-04 2023-07-06 Kenjockety Biotechnology, Inc. Anti-abcg2 antibodies and uses thereof
EP4161564A1 (en) 2020-06-04 2023-04-12 Kenjockety Biotechnology, Inc. Abcg2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
EP4182335A2 (en) 2020-07-14 2023-05-24 Pfizer Inc. Recombinant vaccinia virus
CA3193588A1 (en) 2020-09-02 2022-03-10 Kenjockety Biotechnology, Inc. Anti-abcc1 antibodies and uses thereof
CA3203652A1 (en) 2020-11-13 2022-05-19 William Robert ARATHOON Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof
AU2022413942A1 (en) 2021-12-13 2024-05-30 William Robert Arathoon Living Trust Dated August 29, 2016 Anti-abcb1 antibodies
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US34277A (en) * 1862-01-28 Improvement in lamps
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
FR2629818B1 (fr) * 1988-04-06 1990-11-16 Centre Nat Rech Scient Procede de preparation du taxol
USRE34277E (en) * 1988-04-06 1993-06-08 Centre National De La Recherche Scientifique Process for preparing taxol
MX9102128A (es) * 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
FR2696460B1 (fr) * 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2696458B1 (fr) * 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.

Also Published As

Publication number Publication date
SK43895A3 (en) 1995-08-09
KR100290663B1 (ko) 2001-09-17
CA2146372C (fr) 2003-09-09
JPH08501787A (ja) 1996-02-27
FR2696464A1 (fr) 1994-04-08
GR3022286T3 (en) 1997-04-30
RU95110766A (ru) 1996-12-27
NO313141B1 (no) 2002-08-19
ATE147734T1 (de) 1997-02-15
TW372234B (en) 1999-10-21
FR2696464B1 (fr) 1994-11-10
FI951593A0 (fi) 1995-04-04
HUT72616A (en) 1996-05-28
HU9500970D0 (en) 1995-06-28
CZ284818B6 (cs) 1999-03-17
NO951200L (no) 1995-03-29
FI951593A (fi) 1995-04-04
PL308239A1 (en) 1995-07-24
US5717103A (en) 1998-02-10
JP3064419B2 (ja) 2000-07-12
ZA937316B (en) 1994-04-22
WO1994007876A1 (fr) 1994-04-14
KR950703545A (ko) 1995-09-20
EP0663905B1 (fr) 1997-01-15
ES2096328T3 (es) 1997-03-01
DK0663905T3 (da) 1997-02-03
AU689446B2 (en) 1998-04-02
FI115909B (fi) 2005-08-15
HU225973B1 (en) 2008-02-28
US5977375A (en) 1999-11-02
RU2123493C1 (ru) 1998-12-20
DE69307526T2 (de) 1997-05-22
DE69307526D1 (de) 1997-02-27
NZ256443A (en) 1996-07-26
CZ83995A3 (en) 1995-09-13
PL178090B1 (pl) 2000-02-29
CA2146372A1 (fr) 1994-04-14
AU5114893A (en) 1994-04-26
MX9305764A (es) 1995-01-31
EP0663905A1 (fr) 1995-07-26
NO951200D0 (no) 1995-03-29

Similar Documents

Publication Publication Date Title
SK281035B6 (sk) Spôsob prípravy esterov baccatínu iii alebo 10-desacetylbaccatínu iii, ester baccatínu iii alebo 10-desacetylbaccatínu iii a medziprodukt na uvedený spôsob
KR100311198B1 (ko) 탁산유도체의제조방법
US5861515A (en) Process for the preparation of taxane derivatives
US5637723A (en) Process for preparing taxane derivatives
US5763477A (en) Taxane derivatives from 14-β-hydroxy-10 deacetylbaccatin III
SK285797B6 (sk) Medziprodukt a spôsob prípravy paclitaxelu alebo docitaxelu
US6130336A (en) Process for preparing paclitaxel
SK281075B6 (sk) Spôsob prípravy 7-hydroxytaxánov
SK280576B6 (sk) Spôsob stereoselektívnej prípravy derivátu beta-fe
SK92994A3 (en) Acids anhydrides and method of their preparation and use
RU2320652C2 (ru) Производные таксана, функционализированные по 14-положению, и способ их получения
SK280965B6 (sk) Spôsob prípravy kyseliny 1,3-oxazolidín-5-karboxylovej
KR101003820B1 (ko) 도세탁셀의 제조방법 및 도세탁셀의 제조를 위한 신규한중간체
HUT66773A (en) Method for preparing 13-alpha-cinnamoyl-baccatine iii or 10-deacetyl baccatine iii

Legal Events

Date Code Title Description
MK4A Patent expired

Expiry date: 20131004